Video: How Do We Track Vascular Changes in a Scleroderma Clinic?
Dr. Tracy Frech reviews the different clinical tools that your physician can use to assess your vascular health. This session was recorded in Nashville during the 2015 Scleroderma Foundation National Patient Education Conference.
Scientific Insights Into IBIO-CFB03 Presented at American College of Rheumatology Annual Meeting (ACR)
iBio, Inc., a leader in plant-based biotechnology for developing and manufacturing biological products, announced the presentation at ACR of new information on the mechanism of action of iBio's proprietary product candidate for the treatment of fibrotic diseases, IBIO-CFB03.
On Tuesday, December 1, 2015, charities, families, businesses, community centers, and students around the
world will come together for one common purpose: to celebrate and encourage giving.
Anyone, anywhere can get involved in Giving Tuesday and give back in a way that is meaningful to them.
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
The Scleroderma Foundation is a qualified national nonprofit operating under 501(c)(3) status. The foundation’s federal tax identification number is 52-1375827. Our primary goal is to raise funds for our three-fold mission of support, education and research. The foundation has 20 active chapters and 160 support groups across the country.